Sebastian Hilscher
Overview
Explore the profile of Sebastian Hilscher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waitman K, Martin H, Carlos J, Braga R, Souza V, Melo-Filho C, et al.
bioRxiv
. 2024 Dec;
PMID: 39677737
Highlights: Novel kinase/HDAC inhibitors for cancer treatment were found using machine learning61 QSAR models for hematological cancers and its targets were built and validatedK562, MV4-11, MM1S, NB-4, U937, and HDAC6...
2.
Berluti F, Baselious F, Hagemann S, Hilscher S, Schmidt M, Huttelmaier S, et al.
Arch Pharm (Weinheim)
. 2024 Sep;
357(11):e2400437.
PMID: 39291901
Class I histone deacetylases (HDACs) are considered promising targets in current cancer research. To obtain subtype-selective and potent HDAC inhibitors, we used the aminobenzamide scaffold as the zinc-binding group and...
3.
Baselious F, Hilscher S, Hagemann S, Tripathee S, Robaa D, Barinka C, et al.
Arch Pharm (Weinheim)
. 2024 Jul;
357(10):e2400486.
PMID: 38996352
AlphaFold is an artificial intelligence approach for predicting the three-dimensional (3D) structures of proteins with atomic accuracy. One challenge that limits the use of AlphaFold models for drug discovery is...
4.
Jose-Eneriz E, Gimenez-Camino N, Rabal O, Garate L, Miranda E, Gomez-Echarte N, et al.
Nat Commun
. 2024 Jul;
15(1):5570.
PMID: 38956053
Despite the development of novel therapies for acute myeloid leukemia, outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have...
5.
Baselious F, Hilscher S, Robaa D, Barinka C, Schutkowski M, Sippl W
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38279359
HDAC11 is a class IV histone deacylase with no crystal structure reported so far. The catalytic domain of HDAC11 shares low sequence identity with other HDAC isoforms, which makes conventional...
6.
Tavares M, Kruger A, Yan S, Waitman K, Gomes V, de Oliveira D, et al.
Sci Rep
. 2023 Nov;
13(1):21006.
PMID: 38030668
We report a series of 1,3-diphenylureido hydroxamate HDAC inhibitors evaluated against sensitive and drug-resistant P. falciparum strains. Compounds 8a-d show potent antiplasmodial activity, indicating that a phenyl spacer allows improved...
7.
Abdelsalam M, Zmyslia M, Schmidtkunz K, Vecchio A, Hilscher S, Ibrahim H, et al.
Arch Pharm (Weinheim)
. 2023 Nov;
357(2):e2300536.
PMID: 37932028
Although histone deacetylase (HDAC) inhibitors show promise in treating various types of hematologic malignancies, they have some limitations, including poor pharmacokinetics and off-target side effects. Prodrug design has shown promise...
8.
Sinatra L, Vogelmann A, Friedrich F, Tararina M, Neuwirt E, Colcerasa A, et al.
J Med Chem
. 2023 Oct;
66(21):14787-14814.
PMID: 37902787
Dysregulation of both tubulin deacetylases sirtuin 2 (Sirt2) and the histone deacetylase 6 (HDAC6) has been associated with the pathogenesis of cancer and neurodegeneration, thus making these two enzymes promising...
9.
Zessin M, Meleshin M, Hilscher S, Schiene-Fischer C, Barinka C, Jung M, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108579
Lysine deacetylases, like histone deacetylases (HDACs) and sirtuins (SIRTs), are involved in many regulatory processes such as control of metabolic pathways, DNA repair, and stress responses. Besides robust deacetylase activity,...